Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials

Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials

The data report details the baseline characteristics and observed outcomes among patients included in a large US administrative claims database (Optum Labs Data Warehouse) and those enrolled in the pivotal phase III clinical trials examining apixaban, dabigratan, edoxaban and rivaroxaban versus warf...

Full description

Bibliographic Details
Main Authors:	Peter A. Noseworthy, Xiaoxi Yao, Bernard J. Gersh, Ian Hargraves, Nilay D. Shah, Victor M. Montori
Format:	Article
Language:	English
Published:	Elsevier 2017-10-01
Series:	Data in Brief
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352340917303876

Similar Items

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
by: Xiaoxi Yao, et al.
Published: (2016-02-01)

Non-vitamin K oral anticoagulants (NOACs) in patients with stroke and atrial fibrillation
by: Jovanović Dejana R.
Published: (2020-01-01)

Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
by: Anetta Undas, et al.
Published: (2019-12-01)

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation
by: Peter A. Noseworthy, et al.
Published: (2022-10-01)

Novel Oral Anti Coagulants (NOACs) as Anti Thrombotic on Atrial Fibrillation Patients
by: Abed Nego Okthara Sebayang
Published: (2020-02-01)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
by: Line Melgaard, et al.
Published: (2021-12-01)

Assessment of treatment patterns and patient awareness in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants (ASPECT-NOAC)
by: Özer Badak, et al.
Published: (2022-04-01)

Correction: New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
by: Karen Sheares, et al.
Published: (2020-06-01)

Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study
by: Maurizio Paciaroni, et al.
Published: (2017-12-01)

Contemporary trends and barriers to oral anticoagulation therapy in Non-valvular atrial fibrillation during DOAC predominant era
by: Ojasav Sehrawat, et al.
Published: (2023-06-01)

Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis
by: Lu Wang, et al.
Published: (2023-08-01)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
by: Hyeongsoo Kim, et al.
Published: (2020-01-01)

Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
by: Qiyu He, et al.
Published: (2019-05-01)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
by: Blann A
Published: (2015-08-01)

Prognostic significance of patent foramen ovale in anticoagulated patients with atrial fibrillation
by: Bernard J Gersh, et al.
Published: (2020-06-01)

Assessment of the compatibility of the real-world nonvalvular atrial fibrillation patients in Turkey with the study population of Phase 3 novel oral anticoagulant trials: An auxiliary study of NOAC-TR
by: Sadik Volkan Emren, et al.
Published: (2020-01-01)

Is Atrial Fibrillation Management as Simple as ABC?
by: Xiaoxi Yao, et al.
Published: (2020-05-01)

Prevention of thromboembolic events in patients with atrial fibrillation – new anticoagulants
by: Alexandre Holthausen Campos, et al.
Published: (2011-09-01)

Prevention of thromboembolic events in patients with atrial fibrillation – new anticoagulants
by: Alexandre Holthausen Campos, et al.
Published: (2011-09-01)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
by: Fuwei Liu, et al.
Published: (2022-06-01)

Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial
by: Marleen Kunneman, et al.
Published: (2017-09-01)

Access Site Bleeding Complications with NOACs versus VKAs in Patients with Atrial Fibrillation Undergoing Cardiac Implantable Device Intervention
by: Enrico Guido Spinoni, et al.
Published: (2022-02-01)

AF-React study: Prevalence of thrombotic events in patients with atrial fibrillation receiving NOACs – real-world data analysis from northern Portugal primary healthcare
by: Susana Silva Pinto, et al.
Published: (2024-04-01)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement.
by: Victor Chien-Chia Wu, et al.
Published: (2020-01-01)

ANTICOAGULATION CONTROL AMONG PATIENTS WITH ATRIAL FIBRILLATION
by: Amer Rauf, et al.
Published: (2020-12-01)

Acute Stroke and Atrial Fibrillation: Risk of Incorrect NOAC Dosage When Estimating Renal Function From Plasma Creatinine Only
by: Danial C. Amoey, et al.
Published: (2022-07-01)

Anticoagulant management in patients with atrial fibrillation.
by: Fitzmaurice, D, et al.
Published: (2009)

Prevalence of oral anticoagulation in atrial fibrillation
by: Eduardo Bartholomay, et al.
Published: (2014-09-01)

New Insights into Anticoagulation in Atrial Fibrillation
by: Xiaohan Fan, MD, et al.
Published: (2011-01-01)

New oral anticoagulants in atrial fibrillation
by: L. Sumithra, et al.
Published: (2014-11-01)

New oral anticoagulants for atrial fibrillation
by: Yuliana Yakobus
Published: (2017-06-01)

Evaluation of drug adherence in patients with non-valvular atrial fibrillation according to geographic regions of Turkey: an analysis from NOAC-TR study
by: Volkan Emren, et al.
Published: (2017-12-01)

Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients – A cohort study
by: Wei-Chieh Lee, et al.
Published: (2022-10-01)

Approach to device-detected subclinical atrial fibrillation
by: van Zyl, Martin, et al.
Published: (2017-08-01)

Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
by: Ceren Eyileten, et al.
Published: (2020-04-01)

Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technology
by: Nilay D Shah, et al.
Published: (2020-10-01)

Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study
by: Ömer Gedikli, et al.
Published: (2021-03-01)

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.
by: Wan, Y, et al.
Published: (2008)